← All trials
NCT00468273
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2006
- Primary completion
- May 1, 2009
- Completion date
- Aug 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- FFF EnterprisesLead sponsor
- University of TorontoOverall official - principal investigator
- 1st Allergy & Clinical Research CenterOverall official - principal investigator
- Rush UniversityOverall official - principal investigator
- Allergy, Asthma and Immunology Clinic PAOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Optimal ResearchOverall official - principal investigator
- Allergy Associates of the Palm Beaches, North Palm Beach, FLOverall official - principal investigator
- University of TorontoStudy chair
- Omrix Biopharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.